The evidence-based pharmacotherapy of social anxiety disorder (Q28262456)

https://api.crossref.org/works/10.1017%2FS1461145712000119

Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

The Relationship Between Antidepressant Prescription Rates and Rate of Early Adolescent Suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Psychological and pharmacological treatments of social phobia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Elective mutism: an analysis of 100 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

The assessment and treatment of performance anxiety in musicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Imipramine in the treatment of social phobia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Pharmacological treatment of social anxiety disorder: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

The evidence-based pharmacological treatment of social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Generalizability of clinical trials for alcohol dependence to community samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Social phobia. Comorbidity and morbidity in an epidemiologic sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Citalopram treatment of social anxiety disorder with comorbid major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Levetiracetam in social phobia: a placebo controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Pharmacologic management of anxiety disorders in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Pharmacotherapy of Social Phobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Social phobia: long-term treatment outcome and prediction of response--a moclobemide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Treatment of social phobia with gabapentin: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Fluoxetine for the treatment of childhood anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Efficacy of olanzapine in social anxiety disorder: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

Paroxetine in social anxiety disorder: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Social phobia: a comparative clinical study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Pharmacologic treatment for children and adolescents with anxiety disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Treatment of social phobia with clonazepam and placebo.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Open fluoxetine treatment of mixed anxiety disorders in children and adolescents

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Phenelzine treatment of selective mutism in four prepubertal children

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Cognitive-Behavioral and Pharmacological Treatment for Social Phobia: A Meta-Analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Clonazepam in childhood anxiety disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

The Epidemiology of Social Anxiety Disorder in the United States

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Sertraline for social phobia: a double-blind, placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

https://api.crossref.org/works/10.1017%2FS1461145712000119

1 reference

7 January 2021

A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

The Classification of Phobic Disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Moclobemide in social phobia: a controlled dose-response trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Placebo-controlled trial of moclobemide in social phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Citalopram for social anxiety disorder: an open-label pilot study in refractory and nonrefractory patients.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Fluoxetine treatment of social phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Age of onset in different phobias

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021

Social phobia: a comparison of behavior therapy and atenolol

1 reference

https://api.crossref.org/works/10.1017%2FS1461145712000119

7 January 2021